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Cochrane Reviews summarise best evidence
and should inform guidelines. We assessed
the use of Cochrane Reviews in the UK
guidelines for paediatric respiratory disease.
We found 21 guidelines which made 1025
recommendations, of which 96 could be
informed by a Cochrane Review. In 38/96
recommendations (40%), some or all of the
relevant Cochrane Reviews were not cited. We
linked recommendations to 140 Cochrane
Reviews. In 37/140 (26%) cases, the guideline
recommendation did not fully agree with the
Cochrane Review. Guideline developers may
fail to use Cochrane Reviews or may make
recommendations which are not in line with
best evidence.
INTRODUCTION
Clinical practice guidelines support optimal
decision making in medical care. Guidelines
should use the best available evidence.1
Systematic reviews use transparent criteria
(such as Grading of Recommendations
Assessment, Development and Evaluation
(GRADE)) to evaluate the quality of evi-
dence2 and so systematic reviews (where
available) should be the primary source of
evidence in guidelines. The Cochrane
Collaboration produces systematic reviews
(‘Cochrane Reviews’) using a rigorous meth-
odology. These are peer reviewed at the
protocol and review stage, and are updated
regularly.3 Previous work indicates that
guidelines do not make full use of Cochrane
Reviews.4 5 This represents research
wastage, and may lead to suboptimal
medical care.
Respiratory disease in children is
common—20% of children visiting the
emergency department, with a medical
problem, will have a respiratory illness.6
However, the paediatric respiratory evi-
dence base is limited. Nearly half of chil-
dren with respiratory disease receive a
medication which is off-label or
unlicensed.7 It is particularly important
that guidelines for respiratory disease in
children make the best use of this limited
evidence. We examined the use of evi-
dence from Cochrane Reviews in guide-
lines for respiratory disease in children.
We aimed to understand the use of the
best available evidence in the ﬁeld of
paediatric respiratory medicine. We sys-
tematically examined the use of Cochrane
Reviews in the UK clinical guidelines for
lower respiratory diseases in children and
we examined the agreement between
the guideline recommendations and the
Cochrane Reviews. We investigated the
association between guideline commission-
ing agency, the topic, the publication year
and the use of alternate high-quality evi-
dence on whether Cochrane Reviews were
cited, and whether their conclusions were
followed.
METHODS
We identiﬁed all the respiratory guidelines
in the UK for lower respiratory tract disease
for children via database and web searches.
We simultaneously identiﬁed all the
Cochrane Reviews relevant to paediatric
respiratory medicine, via the Cochrane
library. For each guideline, we included all
recommendations pertaining to an inter-
vention for lower respiratory tract disease
in children. For each recommendation, we
identiﬁed if there was a Cochrane Review
which could inform it, and which had been
published at least 1 year prior to the guide-
line. We mapped each guideline recommen-
dation to relevant Cochrane Reviews.
For each linked guideline recommenda-
tion—Cochrane Review, we categorised
the agreement between the guideline rec-
ommendation and the Cochrane Review
into one of four categories: (i) totally, (ii)
partially, (iii) not in agreement or (iv) a
strong guideline recommendation where
the Cochrane Review concluded that
there was not enough evidence to draw a
conclusion (see online supplementary
tables S1 and S2 for deﬁnitions and exam-
ples). Where guideline recommendations
disagreed with the Cochrane Review, we
categorised the extent of the disagreement.
The protocol (including study eligibility
criteria and statistical analysis plan) was
produced in advance of the data collection,
is available at the University of
Nottingham ePrints server and as online
supplementary ﬁles 2 and 3). Detailed
methods are provided in online
supplementary information.
RESULTS
Guidelines and Cochrane Reviews
identiﬁed
We included 21 guidelines and 236
Cochrane Reviews (see ﬁgure 1). The 21
guidelines made 1025 recommendations,
of which 555 were for treatment of lower
respiratory disease in children. We identi-
ﬁed relevant Cochrane Reviews for 96
(17.3%) of these 555 recommendations.
Of the 96 recommendations that could
use Cochrane Reviews, 28/96 (29%) did
not use any, and 10/96 (10%) did not use
all the available Cochrane Reviews. There
were 140 instances where a Cochrane
Review could be linked to at least one
guideline recommendation. Of these, 103/
140 (74%) were in agreement, 13/140
(9%) were partially in agreement, 5/140
(4%) disagreed and 19/140 (13%) were
strong recommendations but the Cochrane
Review did not draw a conclusion. Few
Cochrane Reviews in paediatric respiratory
medicine were able to draw a strong con-
clusion, 96/283 (34%).
We summarise these data in ﬁgure 2. An
interactive version of this ﬁgure allowing the
reader to directly explore the data within a
web browser is available online here: https://
www.nottingham.ac.uk/~mszap3/interactive_
ﬁgure.html.
Further analysis is presented in the
online supplementary information, includ-
ing a sensitivity analysis of our judgements
in categorising agreement and an analysis
investigating the impact of commissioning
agency, guideline topic, guideline year and
guideline use of alternate high-quality evi-
dence on the use of Cochrane Reviews.
DISCUSSION
We found that 38/96 (40%) of guideline
recommendations did not use all the rele-
vant Cochrane Reviews. The majority of
guideline recommendations were in agree-
ment with Cochrane Review recommen-
dations. We present the data as an
interactive ﬁgure allowing the reader to
explore the links between Cochrane
Reviews and guideline recommendations.
Our results are broadly in keeping with
studies in other ﬁelds such as smoking ces-
sation and neonatal medicine which show
that guidelines do not make the best use
of Cochrane Reviews. Silagy et al4 found
four guidelines for smoking cessation (one
from the UK). In the UK guideline, 16/22
recommendations could have cited a
Cochrane Review but only 8 recommenda-
tions did so. Brok et al5 studied the agree-
ment between guidelines and Cochrane
Reviews for newborns in Denmark.
Compared with our study, they found
similar discrepancies between Cochrane
Reviews and guideline recommendations
—24% were not in agreement (of which
6% partially agreed and 18% disagreed).
Our study is comprehensive, used an a
priori protocol and categorisations were
conducted independently by two investi-
gators. The study has limitations, includ-
ing the subjectivity in decisions regarding
agreement and disagreement. We expand
on this in online supplementary ﬁle 1.
CONCLUSION
In spite of the work of the Cochrane col-
laboration, there are still many treatment
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Figure 1 Flow diagram of the selection of guidelines and Cochrane Reviews.
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Figure 2 Do Cochrane Reviews inﬂuence clinical practice guideline recommendations? Evidence network diagram to show the links between
Cochrane Reviews and Guideline recommendations. Each individual guideline recommendation is represented by a purple node, and each Cochrane
Review by a green node. A solid blue line connecting a guideline recommendation to a Cochrane recommendation indicates that the guideline cited
the Cochrane Review, and the two are in agreement. A broken line indicates that the guideline did not cite the Cochrane Review. A brown line
indicates that the Cochrane Review and guideline were not totally in agreement. Panel A shows all the links. Subsequent panels are subgrouped by
disease topic: B=asthma, C=cystic ﬁbrosis, D=respiratory infections and E=respiratory aspects of critical care. An interactive web-based version of
the evidence network diagram (which loads in all recent major browsers) is available at www.nottingham.ac.uk/~mszap3/interactive_ﬁgure.html and
allows the reader to explore the underlying data further.
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decisions where there is no systematic
review to inform guideline recommenda-
tions. However, we have shown that, even
where a Cochrane Reviews exists, guideline
developers may not make use of it or may
make recommendations contrary to the
ﬁndings of the review. This study demon-
strates that only a minority of recommen-
dations in clinical practice guidelines are
based on the highest quality evidence. A
great deal of money, time and effort goes
into creating and updating Cochrane
Reviews. Not using such evidence in guide-
lines constitutes research waste.
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